Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916 - Wikidata - awgldk - TriplyDB

Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916

Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916

http://www.wikidata.org/entity/Q33432475

about

The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.Update on options for treatment of metastatic castration-resistant prostate cancer Evolving role of bone biomarkers in castration-resistant prostate cancer.Changes of protein expression in prostate cancer having lost its androgen sensitivity.Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER.Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit.Potential utility of cancer-specific biomarkers for assessing response to hormonal treatments in metastatic prostate cancer.Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3 MET and VEGF: synergistic targets in castration-resistant prostate cancer Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients Mathematical modeling of prostate cancer progression in response to androgen ablation therapy.Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials Castration-resistant prostate cancer: systemic therapy in 2012 Predictors of Time to Metastasis in Castration-resistant Prostate Cancer.Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.An update on androgen deprivation therapy for prostate cancer.The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.Impact of Age at Diagnosis on Outcomes in Men with Castrate-Resistant Prostate Cancer (CRPC).Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival Current approaches, challenges and future directions for monitoring treatment response in prostate cancer.Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CT Predicting response to hormonal therapy and survival in men with hormone sensitive metastatic prostate cancer.Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.Novel therapeutics for the management of castration-resistant prostate cancer (CRPC).Testosterone in prostate cancer: the Bethesda consensus.MicroRNAs as putative mediators of treatment response in prostate cancer.Chemotherapy for prostate cancer: when should a urologist refer a patient to a medical oncologist?New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.The utility of prostate-specific antigen in the management of advanced prostate cancer.Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.Degarelix: a review of its use in patients with prostate cancer.PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials.Drug design strategies for the treatment of prostate cancer.'First, do no harm': managing the metabolic impacts of androgen deprivation in men with advanced prostate cancer.

P2860

Q26750672-BB3DC1CA-9A72-4BAF-826A-0650F9ED5C40 Q28072710-F83CAA7B-CCDD-447B-8B83-CE16515B2F5D Q28388750-0448A8BC-12AD-4309-A2F2-C7E6260FABDD Q30574916-BBF73EED-5F82-4D51-8CFE-E638EEDAD7F3 Q33956051-458564D7-2CBF-4E7F-95BC-E9F089573832 Q34023877-838E3179-0B60-4F6F-9851-ADC721B724D8 Q34043941-394861AE-0F1F-4A70-974D-F4E549B1BFEB Q34179268-F3BB34BA-2E39-4D3C-831F-7B20981277BF Q34309132-C6748905-DC1C-4390-962B-81433DDFB175 Q34417941-13CA7DEB-A62D-4AA3-AD82-39DBF6CB3CBA Q34536729-399675A2-7B3E-4481-8528-F93F36B722B9 Q34636636-356C4E45-8EE3-45F2-88F0-74C312C89F4C Q35158676-12F5EF68-87C7-4AE7-BCBA-BD0416CC73C4 Q35269318-6D304A5E-29E5-4594-8FC6-0F979D106F25 Q35575488-2011C476-56A1-4340-9A90-67FAE1E63B19 Q35602593-0CA80295-07D5-4748-B725-5682D7EC6B9C Q35621205-8660B6FF-F05D-463E-A947-ABB05452AB1E Q35656240-53EF9E27-2D26-4B12-BDFC-FF5FD1A45390 Q35865011-E95BE8ED-6838-4C36-B403-1A84EAD2681D Q36056137-E33C3984-5731-4808-AEA0-FD72F074AAD9 Q36243296-F5DEE7FE-1D53-4FDA-888D-1BA880EABF00 Q36289952-D8558423-917F-475A-96B8-D86DF8735761 Q36353287-D975DC6B-75C0-4293-95C1-DB20E5842DD9 Q36746831-DFC3CBD1-993B-4C26-9AC9-0E68E477440B Q36909750-99BD9249-FDD0-49A9-86A6-45247853999D Q37435181-C925F782-A652-4E97-AC6F-51C48B086C3A Q37496697-B78FAA39-80C0-4F38-9484-28C2D3136312 Q37613206-B122F37F-C312-46E9-B82B-F52F33012D7A Q37672267-F2A48FD0-24D0-4D8D-9D7E-8408746F121F Q37950459-286038C1-A56B-494B-85DC-12F07E0DC9F0 Q37963010-D17D1CDC-E6D1-46B8-8410-830AF8B892F8 Q38011943-52A5640D-48B0-4407-8E7F-47958F2B3D3D Q38023123-16CB8562-980C-43E5-8CFC-452294821B8A Q38023124-AE0E8C60-61B1-4939-A607-F26E8ADA4364 Q38119260-D98500C2-7CDF-4A70-B66D-5E9130585F0C Q38168261-3F784AC3-2A05-4264-92CC-215960418EB2 Q38206404-3D8DBD5B-BE37-4CE8-AC5D-F34181C18654 Q38246587-95787A23-2BB5-4760-85CD-0F6334C32D70 Q38264673-5799DE6D-87BD-48B3-BC6A-D65651ACF14B Q38366829-4235EE22-8E6B-4931-B607-D3E756271094

P2860

Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916

http://www.wikidata.org/entity/Q33432475

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Prostate-specific antigen prog ...... ntergroup Study 0162) and 9916

@ast

Prostate-specific antigen prog ...... ntergroup Study 0162) and 9916

@en

type

label

Prostate-specific antigen prog ...... ntergroup Study 0162) and 9916

@ast

Prostate-specific antigen prog ...... ntergroup Study 0162) and 9916

@en

prefLabel

Prostate-specific antigen prog ...... ntergroup Study 0162) and 9916

@ast

Prostate-specific antigen prog ...... ntergroup Study 0162) and 9916

@en

P1433

Q33432475-D68F32DB-4EDB-4A07-BBCF-0CC655275A3F

P1476

Q33432475-1570D9CF-BF61-4CEA-9C4E-A6F98022DBA7

P2093

Q33432475-059B6828-177B-4367-9A24-18AC36B97346

Q33432475-1CFF4D8C-9ED0-427D-939B-0C3E560C4BD9

Q33432475-30B91ACA-709B-4140-81C1-2C81EF53EF1D

Q33432475-318F416D-911A-4B40-AFED-AD07A085B09A

Q33432475-3F3C7D61-A5D8-4591-8C6F-C81853C186BA

Q33432475-3F6429D9-578A-40CC-AE0B-A024621A1EAA

Q33432475-98DFDEB4-333F-4458-92A1-56BAF23E8E3A

Q33432475-9AAA38C8-523D-416E-AE69-C8DA1B7EB51E

Q33432475-A33540D3-ED1C-4006-B704-AB2586234CAE

Q33432475-A4A1948D-1E0B-487C-9B7F-946FB6DDADD8

P2860

Q33432475-3AC141FA-6AE9-47C7-A0BC-F1F5C6E4261A

Q33432475-4346E077-63B4-45F1-94A3-14368123D3EB

Q33432475-48C05377-C0CA-4CCA-9DA7-699EA4D04242

Q33432475-7E611B5E-D3B0-40A8-AEC7-0FDF4FC84E0A

Q33432475-991B8038-5325-48CB-BC0B-A10DC15F8786

Q33432475-C68B8F82-A47D-4AC7-8D57-C58AABC797CE

P304

Q33432475-5C0F8689-5748-4695-9899-1CE72F1E98DD

P31

Q33432475-C8E9DBF6-EDA7-49E7-8504-373E02BAB2AC

P356

Q33432475-8885D7C0-D16E-43D4-9635-687843A51B09

P407

Q33432475-335B35D1-FD8C-47C0-AE04-E2DCBD8AC36D

P433

Q33432475-F49CC974-EFAD-48C3-A717-D4E7CDB6BC16

P478

Q33432475-CDE890D4-8A48-46DD-910C-92237831CF1C

P50

Q33432475-3F698F8D-FE1B-4A8E-BA6A-F0FC08FE85D4

P577

Q33432475-15671FF6-09DE-4580-B094-A8B8142E5BDA

P698

Q33432475-61DA77FF-A7D7-4D64-AE5E-E41BEA396823

P932

Q33432475-C19918C1-AA50-4009-B679-5DA758F01DF2

P356

JCO.2008.19.9810

P1433

Journal of Clinical Oncology

P1476

Prostate-specific antigen prog ...... ntergroup Study 0162) and 9916

@en

P2093

Atif M Akdas

http://www.w3.org/2001/XMLSchema#string

Bryan Goldman

http://www.w3.org/2001/XMLSchema#string

Bryan J Donnelly

http://www.w3.org/2001/XMLSchema#string

Cathy Tangen

http://www.w3.org/2001/XMLSchema#string

Celestia S Higano

http://www.w3.org/2001/XMLSchema#string

Daniel P Petrylak

http://www.w3.org/2001/XMLSchema#string

E David Crawford

http://www.w3.org/2001/XMLSchema#string

Eric J Small

http://www.w3.org/2001/XMLSchema#string

Maha Hussain

http://www.w3.org/2001/XMLSchema#string

Patrick A Burch

http://www.w3.org/2001/XMLSchema#string

P2860

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.

Explained randomness in proportional hazards models.

P304

2450-2456

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.19.9810

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19380444

http://www.w3.org/2001/XMLSchema#string

P932

2684851

http://www.w3.org/2001/XMLSchema#string